Tamtam Try Tamtam free
Enovis logo

Enovis account plan

Developing medical technology solutions

At a glance

Enovis (NYSE: ENOV) is a US medical technology company in orthopedic implants and recovery devices, with FY2025 net sales of $2,248.0 million.

Enovis Corporation (NYSE: ENOV), the former Colfax, develops, manufactures and distributes medical devices for reconstructive surgery, rehabilitation, pain management and physical therapy. It sells to orthopedic specialists, surgeons, physical therapists and retail consumers through distributors, direct salespeople and direct-to-patient channels, with approximately 42% of FY2025 net sales from outside the U.S. In FY2025 net sales were $2,248.0 million (+6.7%) and Adjusted EBITDA $403.0 million, while goodwill impairments of $1,049.8 million produced a net loss of $(1,183.6) million. It employed approximately 7,802 people at December 31, 2025.

Business units

Strategic priorities

Innovation-led growth in Recon
The strategy is "accelerating growth through innovation, expanding market presence in both established and emerging markets", with a pipeline of new product introductions planned for the next 24 months.
Enabling technology and robotics
Enovis plans to bring a knee robot to market within 2 years after acquiring eCential Robotics, alongside its ARVIS Augmented Reality System, and adds a $4 million investment in enabling-technology R&D talent in Q4 2026.
Ambulatory surgery centers
Management sees changing the trajectory of its full offering in ASCs over the next 3 to 5 years as a key opportunity; over 25% of primary knees are now in the ASC.
Operating model and discipline
Since CEO Damien McDonald joined in March 2025, priorities are commercial execution and innovation, operational excellence and financial discipline, run through the Enovis Growth Excellence (EGX) system.
Cash generation
For 2027 the CFO targets at least 50% free cash flow conversion and $100 million of cash generation, with 2026 the last big year of Lima integration investment.

Latest results

In Q3 2026 (quarter ended October 2, 2026) net sales were $558.7 million, up 1.8% reported and 4.6% organic, with Recon up 6.0% and P&R down 1.9% after the Dr. Comfort divestiture. Gross margin rose to 60.8% from 59.9%, helped by tariff refunds, and Adjusted EBITDA was $103.5 million (18.5% margin). Net income was $3.4 million against a $(570.9) million loss a year earlier, which carried a goodwill impairment. Nine-month net sales were $1,730.7 million (+3.5%). The 2026 guidance was narrowed to revenue of $2.32-2.35 billion with about 5% organic growth, and Adjusted EBITDA guidance raised to $428-438 million.

Investments and deals

eCential Robotics acquisition
A securities purchase agreement was signed on September 28, 2026 to acquire eCential Robotics SAS for an enterprise value of approximately €155.0 million, plus up to €35.0 million on milestones; closing is expected in Q4 2026.
Surgical instrument capex
Capex was $197.4 million in 2025, driven by surgical implant instruments for Recon growth, and $133.2 million in the first nine months of 2026.
Bolt-on acquisitions and divestitures
Seven 2025 transactions totalled $36.9 million (distributors, businesses and IP), while Dr Comfort was sold in October 2025 for up to $60 million.
Share buyback
On November 2, 2026 the Board approved a program to repurchase up to $200 million of shares, replacing the $100 million authorisation.
R&D in surgical technology
Recon R&D rose to $83.3 million in 2025 from $55.6 million, invested in surgical productivity solutions and computer-assisted surgery technologies.

Challenges and risks

Goodwill impairments
A $1,049.8 million goodwill impairment in 2025, caused by the decline in share price and market capitalisation, drove a net loss; further declines could trigger more impairments.
Volatile markets
Management describes a choppy market with cancellations, scheduling and co-pay pressure; international P&R in France and Germany is under pressure and the Middle East conflict was a 100 basis point headwind to international growth in Q3 2026.
Tariffs and cost inflation
U.S. tariffs announced in early 2025 raised input costs, and Recon gross margin fell 150 basis points in Q3 2026 on mix and cost inflation.
Integration and leverage
Lima integration costs continue ($9.2 million in Q3 2026); net leverage was 2.9x and eCential will add about 0.5 turn.
Regulation and legal exposure
EU MDR recertification, reimbursement pressure and a False Claims Act investigation of a former independent distributor are named risks.

What leadership says

“Our third-quarter results reflect continued progress against our innovation-led strategy and the benefits of executing with greater alignment, accountability, and discipline.”

Damien McDonald, Chief Executive Officer · Q3 2026 earnings release, 2026-11-05

“We expect to bring the knee robot to market within 2 years and shoulder to follow soon thereafter.”

Damien McDonald, Chief Executive Officer · Q3 2026 earnings call, 2026-11-05

“our focus is really on gaining market share and candidly, not being a victim to the market.”

Damien McDonald, Chief Executive Officer · Q3 2026 earnings call, 2026-11-05

“Since I joined 12 months ago, we have made meaningful changes to our operating model and senior leadership teams, implemented more rigor around daily management and changed company incentive plans to align with our strategic objectives.”

Damien McDonald, Chief Executive Officer · Q1 2026 earnings call, 2026-05-08

Where a supplier can help

Robotics and navigation engineering
Tied to the enabling technology priority and the eCential acquisition: engineering, software and component partners can help bring the knee robot to market within 2 years.
ASC go-to-market support
Tied to the ASC priority: market data, contracting and sales enablement tools can help Enovis target corporate and owner-operated ASCs.
Supply chain cost reduction
Tied to the tariffs and cost inflation challenge: sourcing, freight and lower-cost manufacturing options can protect margins.
Regulatory compliance services
Tied to the regulation challenge: EU MDR certification and compliance services fit a company still working towards MDR certification.
Sales force effectiveness
Tied to the operating model priority: account targeting, pricing and training tools support the EGX-driven push on account acquisition and penetration.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Enovis?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Enovis

What does Enovis do?

Enovis develops, manufactures and distributes medical devices for reconstructive surgery, rehabilitation, pain management and physical therapy, through its Prevention & Recovery and Reconstructive segments.

What is Enovis's revenue?

FY2025 net sales were $2,248.0 million. For 2026 Enovis guides to revenue of $2.32-2.35 billion.

How many employees does Enovis have?

Enovis employed approximately 7,802 people at December 31, 2025.

Who leads Enovis?

Damien McDonald has been CEO since March 2025 and Phillip B. Berry is CFO.

What is Enovis's strategy?

It focuses on innovation-led growth in reconstructive implants, enabling technology such as robotics and augmented reality, ambulatory surgery centers and disciplined execution.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)